表紙
市場調査レポート

D-Pharm Ltd.:製品パイプライン分析

D-Pharm Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256079
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
D-Pharm Ltd.:製品パイプライン分析 D-Pharm Ltd. - Product Pipeline Review - 2015
出版日: 2015年08月26日 ページ情報: 英文 33 Pages
概要

D-Pharm Ltd.は、イスラエルに本社を置く技術志向のバイオ製薬企業で、中枢神経系疾患治療薬の創薬、開発、商品化を行っています。変性疾患および加齢性疾患の薬剤開発に注力しており、製品ポートフォリオには血栓溶解剤のTHR-18、てんかん、片頭痛および双極性障害治療薬のDP-VPA、急性膵炎による細胞のストレスを軽減するDP-b99などがあります。

当レポートでは、D-Pharm Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

D-Pharm Ltd. の基本情報

  • D-Pharm Ltd. の概要
  • 主要情報
  • 企業情報

D-Pharm Ltd. :R&Dの概要

  • 主な治療範囲

D-Pharm Ltd. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

D-Pharm Ltd. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA登録前の製品/併用療法モダリティ
    • 前臨床段階の製品/併用療法モダリティ

D-Pharm Ltd. :薬剤プロファイル

  • DP-VPA
  • DPB-99
  • THR-18
  • DP-NDD

D-Pharm Ltd. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

D-Pharm Ltd.:最近のパイプライン情勢

D-Pharm Ltd.:開発休止中のプロジェクト

D-Pharm Ltd.:開発が中止されたパイプライン製品

D-Pharm Ltd.:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07452CDB

Summary

Global Markets Direct's, 'D-Pharm Ltd. - Product Pipeline Review - 2015', provides an overview of the D-Pharm Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of D-Pharm Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of D-Pharm Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of D-Pharm Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the D-Pharm Ltd.'s pipeline products

Reasons to buy

  • Evaluate D-Pharm Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of D-Pharm Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the D-Pharm Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of D-Pharm Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of D-Pharm Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of D-Pharm Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • D-Pharm Ltd. Snapshot
    • D-Pharm Ltd. Overview
    • Key Information
    • Key Facts
  • D-Pharm Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • D-Pharm Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • D-Pharm Ltd. - Pipeline Products Glance
    • D-Pharm Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • D-Pharm Ltd. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • D-Pharm Ltd. - Drug Profiles
    • DP-VPA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPB-99
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • THR-18
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DP-NDD
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • D-Pharm Ltd. - Pipeline Analysis
    • D-Pharm Ltd. - Pipeline Products by Target
    • D-Pharm Ltd. - Pipeline Products by Route of Administration
    • D-Pharm Ltd. - Pipeline Products by Molecule Type
    • D-Pharm Ltd. - Pipeline Products by Mechanism of Action
  • D-Pharm Ltd. - Recent Pipeline Updates
  • D-Pharm Ltd. - Dormant Projects
  • D-Pharm Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • DPB-99
  • D-Pharm Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • D-Pharm Ltd., Key Information
  • D-Pharm Ltd., Key Facts
  • D-Pharm Ltd. - Pipeline by Indication, 2015
  • D-Pharm Ltd. - Pipeline by Stage of Development, 2015
  • D-Pharm Ltd. - Monotherapy Products in Pipeline, 2015
  • D-Pharm Ltd. - Phase II, 2015
  • D-Pharm Ltd. - Phase I, 2015
  • D-Pharm Ltd. - IND/CTA Filed, 2015
  • D-Pharm Ltd. - Preclinical, 2015
  • D-Pharm Ltd. - Pipeline by Target, 2015
  • D-Pharm Ltd. - Pipeline by Route of Administration, 2015
  • D-Pharm Ltd. - Pipeline by Molecule Type, 2015
  • D-Pharm Ltd. - Pipeline Products by Mechanism of Action, 2015
  • D-Pharm Ltd. - Recent Pipeline Updates, 2015
  • D-Pharm Ltd. - Dormant Developmental Projects,2015
  • D-Pharm Ltd. - Discontinued Pipeline Products, 2015
  • D-Pharm Ltd., Other Locations
  • D-Pharm Ltd., Subsidiaries

List of Figures

  • D-Pharm Ltd. - Pipeline by Top 10 Indication, 2015
  • D-Pharm Ltd. - Pipeline by Stage of Development, 2015
  • D-Pharm Ltd. - Monotherapy Products in Pipeline, 2015
  • D-Pharm Ltd. - Pipeline by Top 10 Target, 2015
  • D-Pharm Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • D-Pharm Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • D-Pharm Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top